3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Rheumatoid Arthritis, Systemic Juvenile
1
Periodic Fevers Syndrome
1
Mevalonate Kinase Deficiency
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma
1
Cryopyrin-Associated Periodic Syndromes
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Arthritis, Juvenile
1
Arthralgia
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
13
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Docetaxel
6
Axitinib
6
Albumin-Bound Paclitaxel
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Nivolumab
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Sorafenib
4
Radiation
4
Irinotecan
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
canakinumab
×
Clear all
NCT03626545
2023-08-21
CANOPY-2
Novartis
Phase 3
Terminated
245 enrolled
29 charts